{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-23-000048","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.579859+00:00","generated_at":"2026-06-14T16:07:26.878157+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcutis CCO Ken Lock resigns; Ayisha Jeter named interim CCO","bullets":["Ken Lock, SVP and CCO since Oct 2019, resigns effective June 2, 2023 to attend to personal matters.","Ayisha Jeter, VP of Market Access since June 2020, appointed interim CCO.","Company has commenced search for a permanent chief commercial officer.","Lock led commercialization of ZORYVE (roflumilast) cream 0.3% for plaque psoriasis."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-23-000048","json":"https://secwatch.observer/filing/0001787306-23-000048.json","markdown":"https://secwatch.observer/filing/0001787306-23-000048.md","text":"https://secwatch.observer/filing/0001787306-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/0001787306-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/arqt-20230522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T16:07:26.878157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71510f0dd0","claim":"Ayisha Jeter was appointed as Interim Chief Commercial Officer at Arcutis Biotherapeutics, Inc..","evidence_excerpt":"The Company has commenced a search for a permanent chief commercial officer and has appointed Ayisha Jeter, who has served as the Company’s Vice President of Market Access since joining the Company in June 2020, as interim chief commercial officer during the transition period.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/0001787306-23-000048-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"81bb801398","claim":"Kenneth Lock resigned as Senior Vice President and Chief Commercial Officer at Arcutis Biotherapeutics, Inc..","evidence_excerpt":"On May 22, 2023, Kenneth Lock notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as Senior Vice President and Chief Commercial Officer of the Company, effective as of June 2, 2023, to attend to personal matters.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/0001787306-23-000048-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Vice President and Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}